Therapeutic Outcome and Prognosis in Dlderly Patients with Non - Hodgkin's Lymphoma / 대한암학회지
Journal of the Korean Cancer Association
;
: 320-330, 1999.
Article
Dans Coréen
| WPRIM
| ID: wpr-96263
ABSTRACT
PURPOSE:
The prognosis of non-Hodgkins lymphoma (NHL) in elderly patients seems to be poorer than that in patients aged less than 60 years. This may be due to the lower tolerance for combination chemotherapy in the elderly. Aggressive combination chemo-therapy, which is the treatment of choice in intermediate and high grade NHL of adulthood, may be associated with unpredictab1y severe and lethal toxicity and worsened quality of life in the elderly. We investigated the treatment responses, toxicities and prognostic factors of NHL in elderly patients treated with combination chemotherapy. MATERIALS ANDMETHODS:
We treated 116 elderly (>60 yrs) patients with NHL between January 1986 and June 1996 with adriamycin-containing regimens, such as CHOP (cyclo- phosphamide, adriamycin, vincristine, prednisolone), BACOP (bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone), and mBACOP (methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone). Patients in this study ranged from 60 to 81 (median 67) years of age. Fifty-five percent of patients were in stage I or II and the rest (45%) were in stage III or IV. The histologic grade was predominantly (91%) of intermediate and high grade type.RESULTS:
The treatment responses were complete (CR) in 55% and partial (PR) in 25%. The median durstion of CR was 32 (3-132) months. The CR rate was significantly higher in patients treated with RDI (relative dose intensity) > 75% than that in the patients treated with RDI 75% vs 75%).CONCLUSION:
Our data suggests that achievement of the CR after combination chemotherpy is the most important prognostic factor in the elderly patients with NHL. Suboptimal chemotherapy (RDI<75%) reduced the complete remission rate without reducing the likelihood of developing severe toxicities. Optimal chemotherapy with supportive cares involving the use of hematopoietic growth factors may be needed to improve the treatment response and the survival in the elderly patients with aggressive NHL.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pronostic
/
Qualité de vie
/
Vincristine
/
Bléomycine
/
Lymphome malin non hodgkinien
/
Maladie de Hodgkin
/
Doxorubicine
/
Analyse multifactorielle
/
Études de suivi
/
Cyclophosphamide
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Adulte très âgé
/
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Cancer Association
Année:
1999
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS